Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations-Reference-Cited by-同舟云学术

Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations

Published:2018-06 Issue: Volume:120 Page:70-74
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Ricciuti Biagio,Baglivo Sara,Ludovini Vienna,Sidoni Angelo,Metro Giulio,Brambilla Marta,Siggillino Annamaria,Reda Maria Sole,Rebonato Alberto,Maiettini Daniele,Chiari Rita

Funder

Italian Association for Cancer Research

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer;Nan;Oncotarget,2017

2. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer;Pao;Nat. Rev. Cancer,2010

3. Uncommon EGFR mutations in advanced non-small cell lung cancer;O’Kane;Lung Cancer,2017

4. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Novello;Ann. Oncol.,2016

5. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy;Kobayashi;Cancer Sci.,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutually exclusive driver mutations identifies 2 separate primaries in a collision tumor initially interpreted as a solitary lung adenocarcinoma with tumor heterogeneity;Respiratory Medicine Case Reports;2024

2. Efficacy of Osimertinib in Afatinib-resistant Lung Cancer Harboring Uncommon EGFR Mutations: Case Report and Literature Review;Clinical Lung Cancer;2021-05

3. Case Report: Outcome of Osimertinib Treatment in Lung Adenocarcinoma Patients With Acquired KRAS Mutations;Frontiers in Oncology;2021-04-22

4. The prevalence and prognostic value of KRAS co‐mutation subtypes in Chinese advanced non‐small cell lung cancer patients;Cancer Medicine;2019-11-10

5. Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance;Cancers;2019-07-01